14-05-2025 15:00 via rocketnews.com

This biotech’s stock rockets on oral obesity drug partnership with Wegovy parent

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments.
Article Attribution | Read More at Article Source
The post This biotech’s stock rockets on oral obesity drug partnership with Wegovy parent appeared first on RocketNews.

Inflation just hit a 4-year low. Don’t expect price relief to last even as trade wars die down.

How Warren Buffett’s biggest investing mistakes actually teach you smart money lessons

The GOP tax bill would give every American newborn a $1,000 ‘MAGA account.’ How would it work — and would it make a difference?

Steel, not energy, is key to coal’s future growth. Here’s why.

‘Be vigilant with your finances’: My IRA had an unknown beneficiary designation. How could this happen?

My wife and I paid off my stepdaughter’s $415K mortgage in exchange for her house, but it’s now worth $310K. Should we sue?

Elon Musk pay talks at Tesla to pit automaker’s premium versus controversial profile